Real-world use of pembrolizumab in Germany: patient characteristics and survival

Background: Pembrolizumab was the drug that incurred the highest costs for statutory health insurance in Germany in 2023. Using real-world data, we aimed to characterize patients treated with pembrolizumab in Germany and describe their overall survival. Materials and Methods: Using claims data, we [for full text, please go to the a.m. URL]

Institutions

Publication Details

Journal
German Medical Science (German Research Foundation)
Published
2025-11-11
DOI
https://doi.org/10.3205/25gaa17
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world use of pembrolizumab in Germany: patient characteristics and survival

German Medical Science (German Research Foundation)
Cancer Immunotherapy and Biomarkers
article

Real-world use of pembrolizumab in Germany: patient characteristics and survival

article en

Abstract

Background: Pembrolizumab was the drug that incurred the highest costs for statutory health insurance in Germany in 2023. Using real-world data, we aimed to characterize patients treated with pembrolizumab in Germany and describe their overall survival. Materials and Methods: Using claims data, we [for full text, please go to the a.m. URL]

German Medical Science (German Research Foundation)
Leibniz Institute for Prevention Research and Epidemiology - BIPS (DE)
Decent work and economic growth
Openalex Percentile: Top 35%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-world use of pembrolizumab in Germany: patient characteristics and survival · German Medical Science (German Research Foundation) (2025) | TGRS Research Map | TGRS